Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/09/2018 | 08:49pm CEST

Levi & Korsinsky announces it has commenced an investigation of Johnson & Johnson (NYSE:JNJ) (“Johnson & Johnson” or the “Company”) concerning possible violations of federal securities laws.

On February 5, 2018, CNBC published an article alleging that “court proceedings could expose potentially damaging documents” related to certain Johnson & Johnson’s talc products. On this news, shares of Johnson & Johnson fell $7.29 per share or over 5%, to close at $130.39 on February 5, 2018. To obtain additional information, go to:

http://www.zlkdocs.com/JNJ-Info-Request-Form-6450

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
11:14aPfizer joins DOJ probe into claims pharma bribes funded Iraqi terrorists
AQ
08/16JOHNSON & JOHNSON : Announces Chris DelOrefice as Vice President of Investor Rel..
AQ
08/16JOHNSON & JOHNSON : Janssen Submits U.S. & EU Regulatory Applications Seeking Ap..
AQ
08/16MEDICAL EDUCATION MARKET TO GROW AT : Medical Education Market – Global I..
AQ
08/16PFIZER : Motion to dismiss Inflectra case denied, but J&J insists Pfizers lawsui..
AQ
08/16JOHNSON & JOHNSON : 'Dermatological Drugs Market Worth $31.97bn in 2021' Says Vi..
AQ
08/16JOHNSON & JOHNSON : Janssen Reports Positive Topline Results for Antiretroviral ..
AQ
08/15JOHNSON & JOHNSON : RAYNHAM - Thanks to a big-time match, a group of local ki
AQ
08/15JOHNSON & JOHNSON : United Way Suncoast names new Sarasota-area president
AQ
08/14JOHNSON & JOHNSON : to Participate in the 2018 Wells Fargo 13th Annual Healthcar..
AQ
More news
News from SeekingAlpha
08/16A Synopsis Of The HIV Market 
08/16White House proposing cuts in opioid production 
08/16Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2018 Update 
08/15'SAFER' DIVIDEND DOW DOGS : Caterpillar, DowDupont; Chevron, Boeing, & Intel, Ca.. 
08/15J&J's long-acting injectable two-drug regimen successful in late-stage HIV st.. 
Financials ($)
Sales 2018 81 133 M
EBIT 2018 25 227 M
Net income 2018 16 036 M
Debt 2018 11 243 M
Yield 2018 2,70%
P/E ratio 2018 19,74
P/E ratio 2019 17,34
EV / Sales 2018 4,45x
EV / Sales 2019 4,21x
Capitalization 350 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 143 $
Spread / Average Target 8,0%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-5.18%347 417
PFIZER14.36%238 136
NOVARTIS-0.83%207 488
ROCHE HOLDING LTD.-2.96%206 696
MERCK AND COMPANY22.36%176 752
AMGEN12.28%126 710